- Verastem (NASDAQ:VSTM) has initiated Phase 2 trial evaluating VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in KRAS mutant non-small cell lung cancer (NSCLC).
- The first part of the study will determine the optimal regimen of either VS-6766 monotherapy or in combination with defactinib. The second phase of the study will examine efficacy and safety parameters of the most effective regimen.
- Last month, the company launched a mid-stage ovarian cancer with VS-6766 and defactinib combination.
- https://seekingalpha.com/news/3644450-verastem-launches-mid-stage-lung-cancer-study-vsminus-6766-defactinib-combo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.